We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fertility‐sparing treatment for early‐stage epithelial ovarian cancer: Contemporary oncologic, reproductive and endocrinologic perspectives.
- Authors
Mandelbaum, Rachel S.; Klar, Maximilian; Takiuchi, Tsuyoshi; Bainvoll, Liat; Matsuzaki, Shinya; Paulson, Richard J.; Matsuo, Koji
- Abstract
Aim: Epithelial ovarian cancer (EOC) can be a devastating diagnosis in women of reproductive age who desire future fertility. However, in early‐stage disease, fertility‐sparing surgery (FSS) can be considered in appropriately selected patients. Methods: This is a narrative descriptive review of the recent literature on FSS for EOC from oncologic, reproductive and endocrinologic perspectives. Results: The recurrence rate following FSS performed for stage I EOC in published retrospective studies collectively is 13% but ranges from 5 to 29%, while mortality ranges from 0 to 18%. Five‐year disease‐free survival following FSS is over 90% but decreases with higher stage and grade. Recurrences following FSS are more likely to be localized with a more favorable prognosis compared to recurrences following radical surgery. Adjuvant chemotherapy is recommended in women with high‐risk disease, and strategies to minimize gonadotoxicity during chemotherapy such as gonadotropin‐releasing hormone (GnRH) agonists may be considered. Oocyte, embryo and/or ovarian cryopreservation can also be offered to patients desiring future biologic children. Reproductive outcomes following FSS, including pregnancy and miscarriage rates, resemble those of the general population, with a chance of successful pregnancy of nearly 80%. Conclusion: In retrospective data, FSS appears to be oncologically safe in stage IA and IC grade 1–2 non‐clear cell EOC. In patients with grade 3 tumors or clear cell histology, treatment can be individualized, weighing a slightly higher risk of recurrence with fertility goals. A multidisciplinary approach with oncology and reproductive endocrinology may be of utility to help these patients achieve their fertility goals.
- Subjects
LUTEINIZING hormone releasing hormone antagonists; CANCER relapse; COMBINED modality therapy; CRYOPRESERVATION of organs, tissues, etc.; ENDOCRINOLOGY; HUMAN reproduction; MISCARRIAGE; ONCOLOGY; TREATMENT effectiveness; PATIENT selection; FERTILITY preservation; OVARIAN epithelial cancer
- Publication
Journal of Obstetrics & Gynaecology Research, 2020, Vol 46, Issue 8, p1263
- ISSN
1341-8076
- Publication type
Article
- DOI
10.1111/jog.14302